Linares Ila M P, Guimaraes Francisco S, Eckeli Alan, Crippa Ana C S, Zuardi Antonio W, Souza Jose D S, Hallak Jaime E, Crippa José A S
Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brasília, Brazil.
Front Pharmacol. 2018 Apr 5;9:315. doi: 10.3389/fphar.2018.00315. eCollection 2018.
Cannabidiol (CBD) is a component of that has a broad spectrum of potential therapeutic effects in neuropsychiatric and other disorders. However, few studies have investigated the possible interference of CBD on the sleep-wake cycle. The aim of the present study was to evaluate the effect of a clinically anxiolytic dose of CBD on the sleep-wake cycle of healthy subjects in a crossover, double-blind design. Twenty-seven healthy volunteers that fulfilled the eligibility criteria were selected and allocated to receive either CBD (300 mg) or placebo in the first night in a double-blind randomized design (one volunteer withdrew from the study). In the second night, the same procedure was performed using the substance that had not been administered in the previous occasion. CBD or placebo were administered 30 min before the start of polysomnography recordings that lasted 8 h. Cognitive and subjective measures were performed immediately after polysomnography to assess possible residual effects of CBD. The drug did not induce any significant effect ( > 0.05). Different from anxiolytic and antidepressant drugs such as benzodiazepines and selective serotonin reuptake inhibitors, acute administration of an anxiolytic dose of CBD does not seem to interfere with the sleep cycle of healthy volunteers. The present findings support the proposal that CBD do not alter normal sleep architecture. Future studies should address the effects of CBD on the sleep-wake cycle of patient populations as well as in clinical trials with larger samples and chronic use of different doses of CBD. Such studies are desirable and opportune.
大麻二酚（CBD）是大麻的一种成分，在神经精神疾病和其他疾病中具有广泛的潜在治疗作用。然而，很少有研究调查CBD对睡眠-觉醒周期可能产生的干扰。本研究的目的是采用交叉双盲设计，评估临床抗焦虑剂量的CBD对健康受试者睡眠-觉醒周期的影响。选择了27名符合入选标准的健康志愿者，采用双盲随机设计，在第一个晚上让他们接受CBD（300毫克）或安慰剂（一名志愿者退出了研究）。在第二个晚上，使用前一晚未给药的物质重复相同的程序。在持续8小时的多导睡眠图记录开始前30分钟给予CBD或安慰剂。多导睡眠图记录后立即进行认知和主观测量，以评估CBD可能的残留效应。该药物未产生任何显著影响（P>0.05）。与苯二氮䓬类和选择性5-羟色胺再摄取抑制剂等抗焦虑和抗抑郁药物不同，急性给予抗焦虑剂量的CBD似乎不会干扰健康志愿者的睡眠周期。本研究结果支持CBD不会改变正常睡眠结构这一观点。未来的研究应探讨CBD对患者群体睡眠-觉醒周期的影响，以及在更大样本和长期使用不同剂量CBD的临床试验中的影响。这样的研究是必要且适时的。
